Newcastle disease virus expressing a dendritic cell-targeted HIV Gag protein induces a potent Gag-specific immune response in mice

Journal of Virology

Volumn 85, Issue 5, 2011, Pages 2235-2246

  Maamary, Jad ^a   Array, Frida ^b   Gao, Qinshan ^a   García Sastre, Adolfo ^a   Steinman, Ralph M ^b   Palese, Peter ^a   Nchinda, Godwin ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HYBRID PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; FEMALE; IMMUNE RESPONSE; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SPLEEN CELL; VACCINATION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; DENDRITIC CELLS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; NEWCASTLE DISEASE VIRUS; VIRAL VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS; MUS; NEWCASTLE DISEASE VIRUS; VACCINIA VIRUS;

EID: 79551694475     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02036-10     Document Type: Article

References (33)

1. Alexander, D. J. 2000. Newcastle disease and other avian paramyxoviruses. Rev. Sci. Tech. 19:443-462.
2. Barouch, D. H., and B. Korber. 2010. HIV-1 vaccine development after STEP. Annu. Rev. Med. 61:153-167. doi:10.1146/annurev.med.042508.093728.
3. Bozzacco, L., et al. 2007. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc. Natl. Acad. Sci. U. S. A. 104:1289-1294. doi:10.1073/pnas. 0610383104.
4. Bukreyev, A., et al. 2005. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 79:13275-13284. doi:10.1128/JVI.79.21.13275-13284.2005. (Pubitemid 41508142)
5. Carnero, E., et al. 2009. Optimization of human immunodeficiency virus Gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 83:584-597. doi:10.1128/JVI.01443-08.
6. Demangel, C., et al. 2005. Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol. Immunol. 42:979-985. doi:10.1016/j.molimm.2004.09.034.
7. Desrosiers, R. C. 2004. Prospects for an AIDS vaccine. Nat. Med. 10:221-223. doi:10.1038/nm0304-221.
8. De Vries, I. J., et al. 2003. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63:12-17. (Pubitemid 36070411)
9. DiNapoli, J. M., et al. 2007. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J. Virol. 81:11560-11568. doi:10.1128/JVI.00713-07. (Pubitemid 47623787)
10. Fellay, J., et al. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944-947. doi:10.1126/science.1143767. (Pubitemid 47301321)
11. Freeman, A. I., et al. 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13:221-228. doi:10.1016/j.ymthe.2005.08.016.
12. Fu, T. M., et al. 2007. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res. Hum. Retroviruses 23:67-76. doi:10.1089/aid.2006.0114.
13. Gao, X., et al. 2001. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344:1668-1675. doi:10.1056/NEJM200105313442203.
14. Gesprasert, G., et al. 2010. HLA-associated immune pressure on Gag protein in CRF01-AE-infected individuals and its association with plasma viral load. PLoS One. 5:e11179. doi:10.1371/journal.pone.0011179.
15. Granelli-Piperno, A., et al. 2005. Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J. Immunol. 175:4265-4273. (Pubitemid 41361960)
16. Grossmann, C., et al. 2009. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic Toll-like receptor ligands. BMC Immunol. 10:43. doi:10.1186/1471-2172-10-43.
17. Harari, A., et al. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211:236-254. doi:10.1111/j.0105-2896.2006.00395.x.
18. Hofmann-Lehmann, R., et al. 2003. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17:157-166. doi:10.1097/01.aids.0000042942.55529.01. (Pubitemid 36183040)
19. Kiepiela, P., et al. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53. doi:10.1038/nm1520.
20. Mahnke, K., et al. 2000. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 151:673-684.
21. Miura, T., et al. 2009. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare Gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphotye [sic] recognition. J. Virol. 83:2743-2755. doi:10.1128/JVI.02265-08.
22. Nakaya, T., et al. 2001. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75:11868-11873. doi:10.1128/JVI.75.23.11868-11873.2001. (Pubitemid 33063278)
23. Nakaya, Y., et al. 2004. Induction of cellular immune responses to simian immunodeficiency virus Gag by two recombinant negative-strand RNA virus vectors. J. Virol. 78:9366-9375. doi:10.1128/JVI.78.17.9366-9375.2004. (Pubitemid 39096546)
24. Nchinda, G., et al. 2010. Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 107:4281-4286. doi:10.1073/pnas. 1000621107.
25. Nchinda, G., et al. 2008. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 118:1427-1436. doi:10.1172/JCI34224.
26. Park, M. S., J. Steel, A. Garcia-Sastre, D. Swayne, and P. Palese. 2006. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. U. S. A. 103:8203-8208. doi:10.1073/pnas.0602566103.
27. Peeters, B. P., O. S. de Leeuw, I. Verstegen, G. Koch, and A. L. Gielkens. 2001. Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine 19:1616-1627.
28. Pitisuttithum, P., et al. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671. doi:10.1086/508748.
29. Price, D. A., et al. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. U. S. A. 94:1890-1895.
30. Rerks-Ngarm, S., et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220. doi:10.1056/NEJMoa0908492.
31. Robert-Guroff, M. 2007. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 18:546-556. doi:10.1016/j.copbio. 2007.10.010.
32. Russell, N. D., et al. 2007. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44:203-212. doi:10.1097/01.qai.0000248356.48501.ff.
33. Schmitz, J. E., et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860.